BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 14, 2011
 |  BioCentury  |  Strategy

Alexion's expansions

Alexion to expand on back of Soliris, acquisitions in rare, severe disorders

Alexion Pharmaceuticals Inc. last week laid out its plans for keeping up the momentum that has resulted in a doubling of market cap in the past year, from $4.1 billion on Feb. 12, 2010, to $8.2 billion on Friday.

The path forward lies in expansion of its Soliris eculizumab franchise and acquisitions of assets that fit with its focus on rare and severe disorders. Two of these - the acquisition of Taligen Therapeutics Inc. and a program from Orphatec Pharmaceuticals GmbH - were announced within the last two weeks.

Alexion also is building a translational organization to advance its early stage assets.

Alexion markets Soliris - its only approved product - in 35 countries for paroxysmal nocturnal hemoglobinuria (PNH). About 8,000-10,000 patients in North America and Western Europe have PNH, which is an acquired mutation that causes all or some of the body's red blood cells to be destroyed.

First approved in the U.S. and EU in 2007, Soliris had $541 million in sales in 2010, up 40% from $387 million in 2009.

On the company's 4Q10 earnings conference call, CEO Leonard Bell said there's still more growth to come from Soliris in its original indication in current territories, as well as in new territories and indications.

Because PNH causes a diverse range of symptoms, it can be difficult to diagnose. Bell said efforts to educate physicians about how to make early diagnosis and treatment of PNH have helped to grow revenues in the company's core territories of the U.S., EU and Japan.

As a result of Alexion's PNH disease awareness and diagnostic...

Read the full 1313 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >